PAIGE DAVIS: Open Payments
NPI 1013447846 · ROGERS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$602 in 33 payments from 10 companies in 2025. Trend: 2023 $153 · 2024 $1,138 · 2025 $602
Food & beverage: $602
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $183 |
| MERZ NORTH AMERICA, INC. | 1 | $117 |
| Janssen Biotech, Inc. | 5 | $91 |
| Aimmune Therapeutics, Inc. | 3 | $59 |
| SK Life Science, Inc. | 2 | $52 |
| PFIZER INC. | 2 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| GENZYME CORPORATION | 1 | $18 |
| Madrigal Pharmaceuticals | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
Products named: Xeomin, TREMFYA, RINVOQ, LINZESS, SKYRIZI, ZENPEP, XELJANZ, VOWST.
Industry payments across AR — which companies pay providers there.
